Compare Neurocrine Biosciences Inc (NBIX) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Vipshop Holdings Ltd - ADR trades at $12.52 (market cap $6.20B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.5× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.76% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VIPS | |
|---|---|---|
Market Cap | $15.77B | $6.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $20.68 |
52-Week Low | $123.10 | $12.51 |
Enterprise Value | $15.78B | $3.02B |
Dividend Yield | — | 4.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Vipshop Holdings trades at $13.03, down 1.29% with bearish technical signals despite attractive valuation metrics including a P/E of 4.21 and P/S of 0.41. Recent earnings showed mixed results with Q2 2026 missing expectations, while revenue has declined from $112.9B in 2023 to $105.9B in 2025. The company maintains strong profitability with 9.82% net margin and robust cash flow generation.
Analyst consensus remains positive with 54% buy ratings, though near-term headwinds from consumer spending caution and competitive pressures create uncertainty. The stock's deep value proposition is balanced against growth challenges, requiring careful monitoring of Q3 2026 earnings results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
